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Serological Responses of Coyotes to Two Commercial
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87015-3653, USA; 3Veterinary Diagnostic Laboratory, Veterinary Clinical Science Building, Kansas State University, Manhattan, Kansas 66506-5600, USA; 4Corresponding author (e-mail: knowlton@cc.usu.edu).

ABSTRACT: Between August 1993 and September 1994 we documented serological responses of coyotes (Canis latrans) vaccinated
with two commercial rabies vaccines licensed
for use in domestic dogs. Serologic responses
were documented by testing for rabies virus
neutralizing antibodies with the rapid fluorescent focus inhibition test (RFFIT) at 30, 90,
180, 270, and 365 days post-vaccination. All
coyotes vaccinated with Imrab 3威 (Rhone-Merieux, Inc.), and 75% of those vaccinated with
Dura-Rab 3威 (Immunovet, Inc.) seroconverted,
as evidenced by the presence of antirabies antibody titers ⱖ1:5 in one or more of the five
post-vaccination samples. The percent of coyotes showing a titer ⱖ1:5 was generally greater
and titer levels appeared higher and more persistent among animals vaccinated with Imrab
3威 than Dura-Rab 3威. Presence of titers via
RFFIT tests demonstrates the antibodies produced in coyotes by these rabies vaccines functionally bind and neutralize rabies virus in vitro,
but these results do not constitute a demonstration of protection required for licensure for
use in coyotes.
Key words: Canis latrans, coyote, immunization, rabies, vaccination.

Rabies, an infectious disease of mammals, is typically fatal once clinical symptoms are evident. Consequently, disease
management concentrates on limiting exposure and immunization through vaccination (Bunn, 1991). Currently, only killed
virus rabies vaccines, which are generally
less immunogenic than modified live vaccines, are licensed for use in the United
States. Some manufacturers incorporate
adjuvants (compounds that increase the
antigenicity) into vaccines to provide higher and more sustained titers (Tizard, 1996;
pp. 275–277).
Susceptibility and immunologic response to rabies virus differs among species (Dreesen, 1999). As a result, rabies
vaccines undergo stringent testing for ef-

ficacy and safety in each species for which
they are licensed (Anonymous, 1992). Because efficacy of rabies vaccines is determined only through costly live virus challenge tests, vaccine manufacturers concentrate licensure efforts on species for which
vaccination offers potential economic return (i.e., domestic pets and farm animals).
Despite lack of licensed rabies vaccines for
most wildlife species, many zoos, wildlife
parks, and research institutions routinely
vaccinate wildlife against rabies in the
hope of conferring some protection for
captive animals and personnel (Jenkins et
al., 2001), but not in lieu of ‘‘appropriate
public health activities that protect humans.’’
The Logan Field Station of the National
Wildlife Research Center (Logan, Utah,
USA) maintains a colony of captive coyotes
(Canis latrans) for research purposes.
Health concerns for animal and personnel
dictate a schedule of vaccination against
common canine and zoonotic pathogens,
including rabies. Coyotes in the colony receive an annual vaccination with a commercial rabies vaccine approved for use in
domestic dogs with the understanding the
vaccine is not licensed for use in coyotes
and cannot be considered legally protective in this species. Live virus challenge
studies are not within the purview of the
Logan facility, but we were able to evaluate the induction and persistence of rabies
virus neutralizing antibodies among captive coyotes over a 1 yr period related to
use of two commercial rabies vaccines licensed for use in domestic dogs.
We started the study in August 1993
with 58 hand-reared coyotes (25 females
and 33 males) about 4 mo of age from the
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captive colony. They were penned in
groups of three until 8-mo-old; thereafter
they were housed in individual kennels or
as male-female pairs in 0.1-ha enclosures.
They were maintained throughout the
study on a food ration prepared for the
local fur industry (Furbreeders Agricultural Cooperative, Logan, Utah) and had access to water ad libitum. Upon completion
of the study in September 1994, coyotes
were returned to the colony.
We evaluated two commercial killed-rabies vaccines. One, Dura-Rab 3威 (Immuno
Vet, Inc., Tampa, Florida, USA; U.S. Veterinary License #302A, Serial #379, Expiration 24Jan94), was a non-adjuvanted vaccine licensed for intramuscular administration. The other, Imrab 3威 (Rhone-Merieux, Inc., Athens, Georgia, USA; U.S.
Veterinary License #298, Serial #12116,
Expiration 10Feb96), was an adjuvanted
(aluminium hydroxide) vaccine licensed
for intramuscular or subcutaneous administration. Venders donating the vaccines
did not provide potency information for
their respective products, although they
were aware of our study intentions.
At the start of the study, coyotes were
stratified by genetic background (i.e., litter) and sex and then randomly assigned
to one of three treatment groups: (1) intramuscular injection of Dura-Rab 3威; (2)
intramuscular injection of Imrab 3威; and
(3) subcutaneous injection of Imrab 3威.
They were serologically tested via rapid
fluorescent focus inhibition test (RFFIT)
to ensure they were negative for rabies virus neutralizing antibody. Vaccines were
then administered as per manufacturers
label instructions using sterile 3 ml syringes and 22 gauge ⫻ 2.5 cm needles. Intramuscular vaccination was by deep injection at a single location in caudal thigh
musculature, while subcutaneous vaccination involved injection in the intrascapular
region. Sera collections were conducted
prior to treatment and on days 30, 90, 180,
270 and 365 post-vaccination. Coyotes
were physically or chemically (i.e., intramuscular injection of 100 mg ketamine hy-
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drochloride and 1 mg acepromazine maleate) restrained and blood (7 ml/animal)
obtained from the cephalic vein of each
subject using evacuated collection tubes.
Tubes were allowed to stand for 1 to 4 hr
at room temperature prior to centrifugation and aspiration of the sera. Sera samples were aliquotted into 2-ml micro-centrifuge tubes and maintained at ⫺70 C for
1 to 3 days prior to shipment. Samples
were shipped overnight on dry ice in insulated containers to Kansas State University (Manhattan, Kansas, USA) where they
were stored at ⫺70 C until analyzed. Rabies virus antibody titers were determined
at the Veterinary Diagnostic Laboratory
(Kansas State University) via RFFIT. We
used analysis of variance (ANOVA) to
compare overall performance of the two
vaccines (P ⱕ 0.05) followed by a post hoc
use of Fisher’s least significant difference
(LSD) multiple comparison test to assess
which individual comparisons were different (P ⱕ 0.05). Fourteen wk after this
study concluded, many of these coyotes
were incorporated into another study involving an oral rabies vaccine. Anamnestic
responses to re-exposure to rabies antigen
in that study provided some additional information relevant to our study.
Serologic testing prior to vaccinations
revealed titers of ⬍1:5 (considered negative) for all study coyotes (Table 1). Overall, 53 of the 58 coyotes (91%) are known
to have seroconverted, as demonstrated by
rabies specific titers ⬎1:5 via RFFIT at
least once among the five sampling periods
during the ensuing year (Table 1). Three
additional animals, for which rabies antibodies were not detected, showed an anamnestic response to an oral rabies vaccine
after this study was concluded, suggesting
memory immune cells to rabies antigen
were present (Van Kampen, 1999).
At 30 days post-vaccination, all 39 coyotes receiving Imrab 3威, regardless of
route of administration, and 13/19 (68%)
of coyotes receiving Dura-Rab 3威 showed
positive titers (Table 1). Absence of detectable rabies antibody in 6 coyotes in the
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latter treatment group on day 30 could be
related to: (1) improper administration of
vaccine; (2) use of an impotent vaccine; (3)
failure of the immune system; or (4) failure to detect an early immunologic response in conjunction with a rapid dissipation of antibodies. Improper vaccine administration seems unlikely since all vaccinations were given by the same
individual via standard protocols, with all
detection failures occurring in the same
treatment. An impotent vaccine seems unlikely since it came from a common lot and
was maintained under appropriate and
identical storage conditions. Failure of the
immune system to function (poor responders) in these individuals is possible, although seemingly unlikely. Extrinsic factors relating to antigen quantity, quality,
and presentation of the vaccine could also
contribute to immunologic failure but this
seems unlikely.
The six coyotes in the Dura-Rab 3威
treatment that were not seropositive on
day 30 post-vaccination may have experienced a rise and fall in anti-rabies antibody
prior to day 30. If this occurred, the immunologic response may have been suboptimal and it is conjectural whether these
animals were adequately protected in the
event of subsequent exposure to rabies virus. It should be noted that four of the six
gave other indications of seroconverting;
one that did not have titers on days 30, 90,
or 180, was seropositive on days 270 and
365, and three of four used in the oral rabies protocol after this study concluded,
showed an anamnestic response, suggesting memory immune cells to rabies antigen were present. At 365 days post-vaccination, 20 of 20 (100%) coyotes receiving
Imrab 3威 intramuscularly, 16 of 19 (84%)
coyotes receiving Imrab 3威 subcutaneously, and eight of 19 (42%) coyotes receiving
Dura-Rab 3威 intramuscularly were seropositive for anti-rabies antibody (Table 1).
Overall, ANOVA revealed a significant
difference in mean titers among the three
treatments (F ⫽ 11.64, df ⫽ 55, P ⬍
0.001). Post hoc use of Fisher’s LSD test

suggests titers associated with intramuscular injections of Imrab 3威 were consistently higher than Durab-3威 injected similarly. Initially, differences among the
treatments were substantive, but they
waned with advancing time (Table 1). A
decrease in circulating antibody can be expected as the protective function of the
immune system shifts from production of
circulating antibody to reliance on memory immune cells to combat exposures to
rabies antigen. Superficially, coyotes receiving Imrab 3威 appeared to maintain
higher and more persistent titers throughout the study (Table 1). This likely reflects
presence of an adjuvant in Imrab 3威, (Tizard, 1996) but might also relate to other
aspects of vaccine composition.
Although differences were not statistically significant (P ⬎ 0.05), coyotes vaccinated with Imrab 3威 intramuscularly appeared to have higher titers compared to
those vaccinated subcutaneously (Table 1).
Similarly, while males seemed to have (1)
a greater percent of subjects with rabies
antibody titers; (2) higher average titers;
and (3) the highest individual titers (Table
1) compared to females, differences were
not significant (P ⬎ 0.05).
Maintenance of high, persistent titers
may provide a measure of protective assurance, but does not necessarily identify
vaccines as superior products because protection against disease also includes the
ability to produce memory immune cells
(Artois et al., 1993). These could result in
anamnestic responses, as evidenced here
by 4 animals that showed titers ⬍1:5 (considered negative) during one sampling but
had substantial titers during a subsequent
sampling, and at least eight animals that
more than doubled antibody levels between post-vaccination samples. In addition, three animals for which we never detected a titer showed an anamnestic response following exposure to an oral rabies
vaccine after this study was over. Although
some animals may be protected at low or
non-detectable titer levels, Bunn et al.
(1984) showed a correlation between high-
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Immunovet, Inc.
Rhone-Mereieux, Inc. (now Merial Limited).
c Titer values expressed as 1:xx, with only ⱖ 5 used to calculate the mean.
d Only one animal in group had titer ⱖ 5.

a

% seropositive:
Pre-vaccination
30
90
180
270
365
Mean titer ⫾ SEc
Pre-vaccination
30
90
180
270
365

Days post-vaccination
(Initial n)

Dura-Rab 3威 (intramuscular)a

0
697
243
346
369
365

⫾
⫾
⫾
⫾
⫾
⫾
0
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57
135
131
132

None
100
100
100
100
100
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(9)

0
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0
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100
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0
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0
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Imrab 3威 (intramuscular)b

0
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206
256
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⫾
⫾
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⫾
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0
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71
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100
100
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0
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⫾
⫾
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⫾

0
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None
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82
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Males
(11)

Imrab 3威 (subcutaneous)b

0
433
178
147
238
245

⫾
⫾
⫾
⫾
⫾
⫾

0
97
34
27
65
78

None
100
84
84
84
84

All
(19)

TABLE 1. Percent seropositive, mean titers, and standard errors (SE) of coyote sera at five sampling periods after being vaccinated with rabies vaccines licensed for
use in domestic dogs.
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er antibody titers and higher survival rates
of dogs during live virus challenge. The
level of antibody necessary to confer protection in the coyote is not known and can
only be determined through controlled
challenge studies utilizing a virulent rabies
virus.
Efforts to compare titers in coyotes and
dogs receiving the same vaccine are subjective because titer information collected
by manufacturers is proprietary and not
readily available. In addition, there are significant differences in species susceptibility to various strains of rabies virus, with
titers that are protective in one species
sometimes failing to protect another. Data
on dogs provided by manufacturers suggests the titers among coyotes immunized
with Dura-Rab 3威 were lower and less
persistent than among dogs vaccinated
with the same product. However, titers appeared similar between coyotes and dogs
vaccinated with Imrab 3威.
One goal of vaccination is to protect animals from disease by producing antibodies that effectively bind and neutralize a
pathogen. The use of RFFIT in this study
essentially demonstrates this function.
RFFIT titers are determined by incubating sera dilutions with live rabies virus
with the antibody binding and neutralizing
the virus providing a quantitative assay of
the sample. The resulting titers demonstrate the antibody produced was functional in vitro.
Our study demonstrated that coyotes
can produce rabies specific antibody in response to vaccination with two commercial
rabies vaccines licensed for use in domestic dogs. Furthermore, the antibodies produced were capable of binding and neutralizing live rabies virus in vitro. While it
is reasonable to infer a measure of protection was conferred to coyotes receiving
these vaccines, confirmation of such protection can only be obtained through live
rabies challenge tests. Research on other

species suggests that high, persistent titers
are usually protective for most individuals.
We are grateful to the staff and students
associated with the Logan Field Station of
the National Wildlife Research Center
(NWRC) for their assistance in handling
animals and taking blood samples. This
study was conducted under the guidance
of the NWRC animal care and use committee under protocol QA-345. The Veterinary Diagnostic Laboratory at the Kansas State University supported the antibody assay aspects of the study. RhoneMereieux, Inc. (now Merial, Limited) and
Immunovet, Inc. graciously donated the
vaccines for this study. Identification and
use of trade names and products does not
imply endorsement by the federal government.
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